S. Chennoufi

Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors.

J. Bendell, S. Antonia, F. Beier, 2019, Journal of Clinical Oncology.

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

A. Ravaud, Y. Vugmeyster, M. Sznol, 2023, Journal for ImmunoTherapy of Cancer.

Digital Commons@Becker Digital

F. Saad, A. Ravaud, A. Armstrong, 2023 .

Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours

Y. Vugmeyster, M. Sznol, J. Gulley, 2019, Annals of Oncology.

265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort

A. Ravaud, Y. Vugmeyster, L. Dirix, 2020 .

Digital Commons@Becker Digital

A. Ravaud, Y. Vugmeyster, M. Sznol, 2023 .